FI3694522T3 - Kaksikerroksinen lääketablettiformulaatio - Google Patents

Kaksikerroksinen lääketablettiformulaatio

Info

Publication number
FI3694522T3
FI3694522T3 FIEP18866268.8T FI18866268T FI3694522T3 FI 3694522 T3 FI3694522 T3 FI 3694522T3 FI 18866268 T FI18866268 T FI 18866268T FI 3694522 T3 FI3694522 T3 FI 3694522T3
Authority
FI
Finland
Prior art keywords
sodium
lamivudine
layer
dolutegravir
povidone
Prior art date
Application number
FIEP18866268.8T
Other languages
English (en)
Finnish (fi)
Inventor
Jonathan Kaye
Original Assignee
Viiv Healthcare Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viiv Healthcare Co filed Critical Viiv Healthcare Co
Application granted granted Critical
Publication of FI3694522T3 publication Critical patent/FI3694522T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FIEP18866268.8T 2017-10-13 2018-10-08 Kaksikerroksinen lääketablettiformulaatio FI3694522T3 (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762571863P 2017-10-13 2017-10-13
US201862634317P 2018-02-23 2018-02-23
PCT/US2018/054825 WO2019074826A2 (en) 2017-10-13 2018-10-08 FORMULATION OF BICOLET PHARMACEUTICAL TABLET

Publications (1)

Publication Number Publication Date
FI3694522T3 true FI3694522T3 (fi) 2026-02-05

Family

ID=66101717

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP18866268.8T FI3694522T3 (fi) 2017-10-13 2018-10-08 Kaksikerroksinen lääketablettiformulaatio

Country Status (18)

Country Link
US (1) US20200230141A1 (https=)
EP (2) EP4667003A3 (https=)
JP (2) JP7774958B2 (https=)
KR (2) KR20200070246A (https=)
CN (2) CN117281788A (https=)
AU (1) AU2018347990B2 (https=)
BR (1) BR112020006783A2 (https=)
CA (1) CA3078624A1 (https=)
CL (1) CL2020000959A1 (https=)
ES (1) ES3056013T3 (https=)
FI (1) FI3694522T3 (https=)
IL (1) IL273704B2 (https=)
MX (1) MX2020003377A (https=)
PL (1) PL3694522T3 (https=)
PT (1) PT3694522T (https=)
TW (1) TWI841539B (https=)
WO (1) WO2019074826A2 (https=)
ZA (1) ZA202002263B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3920927A1 (en) * 2019-02-05 2021-12-15 VIIV Healthcare Company Method for treating hiv with dolutegravir and lamivudine
WO2021116244A1 (en) * 2019-12-12 2021-06-17 Sandoz Ag Modulation of drug release and bioavailability of compositions containing dolutegravir sodium and other anti hiv drugs
CN111991558B (zh) * 2020-08-28 2022-08-09 安徽贝克生物制药有限公司 一种抗逆转录病毒药物组合物及其制备方法
CN114191404B (zh) * 2022-01-10 2023-06-27 安徽贝克生物制药有限公司 一种多替拉韦片剂及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2744019C (en) 2008-12-11 2017-03-14 Shionogi & Co., Ltd. Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
US9713622B2 (en) * 2009-11-20 2017-07-25 Université Versailles Saint-Quentin-En-Yvelines Schedules for administering combination therapies useful for treating persons afflicted with the human immunodeficiency virus (HIV)
PE20121524A1 (es) * 2010-01-27 2012-12-03 Viiv Healthcare Co Combinaciones de compuestos que comprenden inhibidores de la integrasa de vih y otros agentes terapeuticos
US20170189402A1 (en) * 2012-03-28 2017-07-06 Abbvie Inc. Solid dosage forms
CA2885763C (en) * 2012-10-23 2021-04-06 Cipla Limited Pharmaceutical antiretroviral composition
WO2014184553A1 (en) 2013-05-15 2014-11-20 Cipla Limited Pharmaceutical antiretroviral compositions
US10189860B2 (en) * 2014-07-29 2019-01-29 Lek Pharmaceuticals D.D. Hydrates of dolutegravir sodium
CN106860464A (zh) * 2017-02-16 2017-06-20 江苏艾迪药业有限公司 用于联合抗病毒治疗的药物组合物及应用

Also Published As

Publication number Publication date
EP4667003A3 (en) 2026-02-25
KR20250004136A (ko) 2025-01-07
PL3694522T3 (pl) 2026-03-02
ZA202002263B (en) 2024-10-30
CN117281788A (zh) 2023-12-26
WO2019074826A2 (en) 2019-04-18
IL273704B1 (en) 2024-02-01
CN111246851A (zh) 2020-06-05
JP7774958B2 (ja) 2025-11-25
MX2020003377A (es) 2020-09-28
EP3694522A4 (en) 2021-08-04
TW201927290A (zh) 2019-07-16
BR112020006783A2 (pt) 2020-10-06
IL273704B2 (en) 2024-06-01
EP3694522A2 (en) 2020-08-19
CL2020000959A1 (es) 2021-02-26
TWI841539B (zh) 2024-05-11
AU2018347990A1 (en) 2020-04-23
KR20200070246A (ko) 2020-06-17
EP3694522B1 (en) 2025-11-26
PT3694522T (pt) 2025-12-15
WO2019074826A3 (en) 2020-04-02
JP2025165977A (ja) 2025-11-05
RU2020118376A3 (https=) 2022-02-01
CA3078624A1 (en) 2019-04-18
IL273704A (en) 2020-05-31
US20200230141A1 (en) 2020-07-23
EP4667003A2 (en) 2025-12-24
RU2020118376A (ru) 2021-11-15
AU2018347990B2 (en) 2021-09-09
JP2020536931A (ja) 2020-12-17
ES3056013T3 (en) 2026-02-17

Similar Documents

Publication Publication Date Title
FI3694522T3 (fi) Kaksikerroksinen lääketablettiformulaatio
IL305910B1 (en) Oral dosage formulation of {[ 5-(3- (chlorophenyl)- 3-hydroxypyridine-2- carbonyl] amino} acetic acid
BR112018009447A2 (pt) composição para a formação in-situ, camada, pele protética, kit, método para tratar um ou mais sintomas de pele, método para tratar um ou mais sintomas de uma condição de função de barreira de pele, método para entregar um agente, método para mascarar, esconder ou cobrir uma ou mais condições de função de barreira de pele, método para ocluir a pele em um paciente, método para modificar função de pele
SE0202462D0 (sv) Novel use
HRP20180455T1 (hr) Natrijev (2r, 5s, 13ar) -7, 9-diokso-10- ( (2,4,6-trifluorobenzil) karbamoil) -2, 3, 4, 5, 7, 9, 13, 13a-oktahidro-2, 5-metanopirido [1’,2’ : 4.5]pirazino [2,1-b]oksazepin-8-olat
FI3817751T3 (fi) Vedettömän natriumtiosulfaatin formulaatioita
BR0309562A (pt) Derivados de isoquinolina
RU2008135718A (ru) Композиции клопидогреля бисульфата
EA201891413A1 (ru) Фармацевтическая композиция, содержащая безводный дазатиниб
BR112023025841A2 (pt) Forma cristalina de tolebrutinibe, método de preparação para mesma e uso da mesma
JP2016135782A5 (https=)
BR112023019657A2 (pt) Antagonista de abhd6
AR045070A1 (es) Preparados farmaceuticos topicos de acido ascorbico con efecto post-antimicotico
WO2022023533A3 (en) Antiviral use of liraglutide and gefitinib
US20080216208A1 (en) Waltco LSG (Lotionizing/Sanitizing Gloves)
IL275144B2 (en) Pharmaceutical formulation
MX2023001785A (es) Formulacion compuesta para tratamiento de diabetes mellitus tipo 2.
Hooker et al. Absorption of sulfanilamide from burned surfaces
Dadhwal et al. Vasopressin-induced ST-elevation myocardial infarction
JP2007330743A (ja) 外反母趾・内反小指の予防矯正サポーター
Hidalgo-Zambrano et al. Electrocardiographic changes in patients with chikungunya fever.
HRP20230208T1 (hr) MEZILATNA SOL AMINO-LUPANSKOG SPOJA S INHIBITORSKOM AKTIVNOŠĆU SAZRIJEVANJA HIV-a
Smith The Prevention, Symptoms, and Treatment of Tetryl Dermatitis
WO2010143818A3 (ko) 항균, 소취, 방오 및 음이온 방출이 되는 기능성 위생복 및 환자복
BR112018077144A2 (pt) cianoglucosídeo, composição farmacêutica, e, método para tratar ou melhorar diabetes